APRI (Aprinoia Therapeutics) EV-to-EBIT: 0.00 (As of Jul. 13, 2026)


What is Aprinoia Therapeutics EV-to-EBIT?

Aprinoia Therapeutics APRI EV-to-EBIT is 0.00 as of Jul. 13, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Aprinoia Therapeutics's Enterprise Value is $0.00 Mil. Aprinoia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-23.71 Mil. Therefore, Aprinoia Therapeutics's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Aprinoia Therapeutics's EV-to-EBIT or its related term are showing as below:

APRI's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 14.29
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Aprinoia Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil. Aprinoia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-23.71 Mil. Aprinoia Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

Aprinoia Therapeutics  (NAS:APRI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Aprinoia Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-23.711/0
= %

Aprinoia Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-23.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics EV-to-EBIT Related Terms

Aprinoia Therapeutics EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics EV-to-EBIT Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT 0.00 0.00 0.00 0.00 0.00

APRI vs : EV-to-EBIT Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's EV-to-EBIT falls into.


Aprinoia Therapeutics EV-to-EBIT Calculation

Aprinoia Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-23.711
=0.00

Aprinoia Therapeutics's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-23.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.00 mean?
Aprinoia Therapeutics (APRI) has a EV-to-EBIT of 0.00 as of Jul. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' EV-to-EBIT too high?
Aprinoia Therapeutics' current EV-to-EBIT is 0.00.
How does Aprinoia Therapeutics' EV-to-EBIT compare to ?
Aprinoia Therapeutics' EV-to-EBIT of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 14.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.29, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aprinoia Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprinoia Therapeutics's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current EV-to-EBIT is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.